Clinical trials: Glial Tumors
Recurrent High Grade Glioma
Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma
The study is aimed to evaluate efficacy and safety of re-irradiation for patients with recurrent high grade gliomas after other treatment.
- Trial name
- NCT02567539
- Testing
- IMRT with or without radiosensitive therapy, Radiosensitive therapy
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- Istituto Clinico Humanitas
Glioblastoma
Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma
This is an open-label, single arm, Phase 1 study to assess the safety and tolerability of macitentan in combination with dose-dense temozolomide in adult patients with recurrent glioblastoma or gliosarcoma.
- Trial name
- NCT01499251
- Testing
- Phase 1 Dose Escalation, Phase 1b, Ancillary Study
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Actelion
Glioblastoma Multiforme, Cognition Disorders
Bevacizumab and Lomustine for Recurrent GBM
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Glioblastoma Multiforme, Cognition Disorders, Disability Evaluation
- Trial name
- NCT01290939
- Testing
- bevacizumab, lomustine, DNA methylation analysis
- Where
- 2 sites in Netherlands
- Volunteers
- 592 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioblastoma Multiforme
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy.
- Trial name
- RESTORE (NCT03862430)
- Testing
- NanO2TM
- Where
- 12 sites in United States
- Volunteers
- 87 people
- Sponsor
- NuvOx LLC
Glioblastoma, Glioblastoma Multiforme
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize…
- Trial name
- NCT05281731
- Testing
- Sonobiopsy, Research blood, Cancer Personalized Profiling
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Sarcoma, Osteosarcoma
my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
This study aims to design and test a novel, personalized digital intervention-my.naviGATE-for adolescent and young adults (AYA) with cancer.
- Conditions
- Sarcoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma
- Trial name
- NCT07516353
- Testing
- my.naviGATE Digital Tool
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- Dana-Farber Cancer Institute
Neurofibromatosis 2, Vestibular Schwannoma
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
The purpose of this study is to determine if Lapatinib has any effect on tumors found in patients with Neurofibromatosis Type 2 (NF2). NF2 is a condition that mainly affects the skin and nervous system.
- Trial name
- NCT00973739
- Testing
- Lapatinib
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Glioma
Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas
The NOA-16 trial is the first-in-man trial of the IDH1 (isocitrate dehydrogenase type 1) peptide vaccine targeting the IDH1R132H mutation (amino acid exchange from arginine to glutamine at position 132 of IDH1).
- Trial name
- NOA-16 (NCT02454634)
- Testing
- IDH1 peptide vaccine
- Where
- 8 sites in Germany
- Volunteers
- 39 people
- Sponsor
- National Center for Tumor Diseases, Heidelberg
Medulloblastoma
Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults with Recurrent Medulloblastoma
The purpose of this study is to establish the safety of infusions of panobinostat (MTX110) into the fourth ventricle of the brain or tumor resection cavity in patients with recurrent medulloblastoma and to assess the antitumor…
- Trial name
- NCT04315064
- Testing
- Treatment with MTX110
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- The University of Texas Health Science Center, Houston
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Expanded Access to ANG1005 for Individual Patients
This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient…
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis
- Trial name
- NCT02755987
- Testing
- ANG1005
- Where
- 2 sites in United States
- Sponsor
- Angiochem Inc
Brain and Central Nervous System Tumors
Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors
RATIONALE: Drugs used in chemotherapy, such as thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00313521
- Testing
- thiotepa, adjuvant therapy, radiation therapy
- Volunteers
- 30 people
- Sponsor
- Children's Cancer and Leukaemia Group
Heathy Volunteer, Parkinsonian Syndromes
Ultralow Dose PET Imaging of 18F-FDOPA
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Parkinsonian syndromes, neuroendocrine tumors, and gliomas detection and monitoring.
- Conditions
- Heathy Volunteer, Parkinsonian Syndromes, Neuroendocrine (NE) Tumors, Gliomas
- Trial name
- NCT07542158
- Testing
- 18F-FDOPA
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Akiva Mintz
Glioma, Malignant
ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
This is a phase 1b study of P30-linked EphA2, CMV pp65, and survivin vaccination (collectively called the P30-EPS vaccine) in HLA-A*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health…
- Trial name
- ETAPA I (NCT05283109)
- Testing
- Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine, Hiltonol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Glioblastoma
Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma
This is a multi-institutional phase III clinical study of interventional type. The trial will include 220 patients with confirmed unifocal glioblastoma over a period of 3 years + 3 years of follow up.
- Trial name
- SPECTRO GLIO (NCT01507506)
- Testing
- Radiotherapy, Experimental arm
- Where
- 12 sites in France
- Volunteers
- 180 people
- Sponsor
- Institut Claudius Regaud
Advanced Glioblastoma Patients
The Safety and Effectiveness of NV-A01 in Glioma Patients
The goal of this clinical trial is to learn about the safety and effectiveness of NV-A01 in the treatment of advanced glioma patients. The main questions it aims to answer are: 1.
- Trial name
- NCT06193538
- Testing
- Recombinant NV-A01 adenovirus injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College
Glioblastoma
Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas
This research study is being done to see if lymphocytes can be collected from patients with high grade gliomas before they start standard radiation and chemotherapy.
- Trial name
- NCT01653834
- Testing
- Lymphocyte harvesting & reinfusion
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma, MGMT-Unmethylated Glioblastoma
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This Phase I study investigated the side-effects and best dose of microtubule-targeted agent BAL101553 when given together with radiation therapy in treating patients with newly-diagnosed O6-methylguanine-DNA methyltransferase…
- Trial name
- NCT03250299
- Testing
- Microtubule-Targeted Agent BAL101553, Radiation Therapy
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Basilea Pharmaceutica
Glioblastomas, Sarcoma
Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers
Background: People cope with cancer in different ways. Mindfulness means focusing on the present moment with an open mind. Researchers want to see if this can help children and young adults with a high-grade high-risk cancer with…
- Conditions
- Glioblastomas, Sarcoma, Astrocytoma, Brain Cancer
- Trial name
- NCT03538587
- Testing
- Enhanced Mindfulness Intervention, Psychoeducation
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Leukemia
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial
RATIONALE: Gathering information about why patients or their guardians agree or decline to participate in the optional pharmacokinetic portion of a phase I treatment study may help doctors plan clinical trials in the future.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00890435
- Testing
- questionnaire administration, psychosocial assessment and care
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Children's Oncology Group
Ependymoma, High Grade Gliomas
Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
Pediatric patients 6-21 years of age with supratentorial recurrent, refractory, or progressive pediatric ependymoma and high-grade glioma (HGG) will be included in this study of treatment with Rhenium-186 Nanoliposome (186RNL).
- Trial name
- NCT07061626
- Testing
- Rhenium-186 Nanoliposome
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Cerenome
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.